MedTrace Logo

A Genome-Wide Scan For Quantitative Trait Loci of Serum Bilirubin - A Framingham Study

NCT00340509 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1888

Last updated 2019-12-16

No results posted yet for this study

Summary

Studies have shown that there is a significant association between serum bilirubin concentrations and risk of coronary artery disease (CAD). So far, no linkage analysis in humans between serum bilirubin and DNA markers has been reported. The purpose of this protocol is to identify chromosome regions that contain quantitative trait loci (QTL) involved in serum bilirubin metabolism and bilirubin concentration. In the Framingham Study, a 10cM genome scan (about 400 markers) has been conducted in more than three hundred families. Serum bilirubin was measured in the first and second exams of the Framingham Offspring. These data provide us the opportunity to undertake linkage analyses to map QTL of serum bilirubin.

Conditions

  • Genetics

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Gang PH Zheng, Ph.D. · National Heart, Lung, and Blood Institute (NHLBI)

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-26
Completion
2013-07-23

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00340509 on ClinicalTrials.gov